The move toward Open Science is clashing with the 2026 surge in private-equity-funded university labs. In fact, the Tyton Partners 2026 Report suggests that institutions are increasingly relying on these private partnerships to offset enrollment losses, bringing into question: does the corporate-funding of university labs present a problematic conflict of interest?
For Discussion:
- How would you handle a situation where a graduate student discovers a breakthrough but is legally barred by a corporate partner from presenting it at a faculty colloquium?
- How do you assess research excellence when the research cannot be shared–and thus interrogated– with and by the broader academic community?
